摘要
免疫缺陷动物模型用于对肿瘤机制和治疗的研究,并且普遍应用于临床前。但物种特异性差异阻碍了实验结果的可靠性,物种的特异性差异导致临床治疗失败率超过80%,在评估抗癌治疗的试验中成功率也低于10%。所以人源化肿瘤标本异种移植模型(PDX)能够尽可能的模拟人体内肿瘤生长的微环境,为肿瘤药物的安全性与有效性奠定基础。但PDX肿瘤模型也有自身的局限性,比如无法体现出肿瘤生长个体化的差异性,所以双人源化小鼠肿瘤模型(Hu-PDX模型)弥补了这项缺憾。本文总结了PDX模型发展史,PDX模型特征和优缺点,PDX模型的类型,以及最新进展(Hu-PDX模型)。
Immunodeficiency animal models were used for the study of tumor mechanism and treatment, and widely used in preclinic. However, species-specific differences hinder the reliability of experimental results, leading to the failure rate of clinical treatment exceeding 80%, and the success rate of trials evaluating anticancer treatment is also less than 10%. Therefore, xenotransplantation model of humanized tumor specimens(PDX) simulates the microenvironment of tumor growth in human body as much as possible, laying a foundation for the safety and effectiveness of tumor drugs. However, the PDX tumor model also has its own limitations, for example, it cannot reflect the individualized difference of tumor growth, so the dual-source mouse tumor model(hu-pdx model) makes up for this deficiency. In this review, the development history of PDX model, the characteristics and advantages and disadvantages of PDX model, the types of PDX model, and the latest progress(Hu-PDX model) are summarized.
作者
杨义
景治涛
YANG Yi;JING Zhi-tao(Department of Laboratory Animal Science, China Medical University, Shenyang 110122, China;Department of Neurosurgery, The First Hospital, China Medical University, Shenyang 110122, China)
出处
《解剖科学进展》
2019年第4期480-483,共4页
Progress of Anatomical Sciences
基金
国家自然科学基金青年基金(81101917)
